Investigators at Weill Cornell Medicine have identified significant differences in the molecular characteristics of tumors from younger and older cancer patients across several cancer types.
Researchers at Weill Cornell Medicine have discovered how drugs can affect various membrane-spanning proteins in addition to their intended target, potentially causing unwanted side effects.
The master regulator behind the development of antibody-producing cells has been identified in a study by investigators at Weill Cornell Medicine. The findings provide new insight into the inner workings of the immune system and may help understand how tissues develop and how certain cancers arise.
A team co-led by scientists at Weill Cornell Medicine has revealed in detail how the most common primary eye cancer in adults, uveal melanoma (UM), can progress from a slow-growing, “indolent” state to a lethal metastasizing state. The discovery is a significant advance in fundamental cancer research that also suggests new strategies for treatment.
A powerful immune-suppressing molecule produced by the body may hold the key to better treatments for autoimmune and inflammatory diseases, as well as for some cancers, according to a study by researchers at Weill Cornell Medicine and the University of Perugia.
Researchers at Weill Cornell Medicine have identified a population of neurons that drive animal brains to initiate actions without prompting from an external stimulus such as food or prey.
Scientists at Weill Cornell Medicine have developed a computational technique that greatly increases the resolution of atomic force microscopy, a specialized type of microscope that “feels” the atoms at a surface.
The structure and function of an important protein that transports essential omega-3 fatty acid molecules from the bloodstream into the brain has been determined by a team led by scientists at Columbia University Vagelos College of Physicians and Surgeons, Weill Cornell Medicine, and Duke-NUS Medical School.
About 12,000 bacteria and viruses collected in a sampling from public transit systems and hospitals around the world from 2015 to 2017 had never before been identified.
Two distinct diagnostic tests, a host/pathogen RNA sequencing platform, and spatially-resolved tissue mapping tools were created by a multidisciplinary team of Weill Cornell Medicine and NewYork-Presbyterian Hospital-led researchers and used to map SARS-CoV-2 infections at the height of the initial COVID-19 outbreak in New York City.
As the COVID-19 pandemic enters its second year, scientists are urgently investigating ways to detect signs of the SARS-CoV-2 virus before an outbreak emerges.
Researchers at Weill Cornell Medicine and Cornell University’s Ithaca campus have developed a new computational method for studying genetic and environmental interactions and how they influence disease risk.
Space travel, illnesses like COVID-19, and climbing Mount Everest can trigger the body’s stress response systems in similar ways, according to new studies by Weill Cornell Medicine, space agencies and many other investigators.
Physicians and scientists at Weill Cornell Medicine and NewYork-Presbyterian have rapidly mobilized to confront the COVID-19 pandemic, focusing a broad spectrum of expertise on the critical issues the disease is posing to healthcare workers and public health officials.
With the goal of advancing the fight against COVID-19, the Partners of Citadel and Citadel Securities have made a $2 million gift to Weill Cornell Medicine to develop new approaches to protect people from the disease and identify new cases of it.
The scope of the DNA changes that drive cancers has been illuminated as never before in a set of studies by a large international scientific team including Weill Cornell Medicine researchers. In six studies published Feb. 5 in Nature, and 18 papers in other Nature-affiliated journals, this scientific consortium reported the results from analyses of DNA from more than 2,600 biopsied tumor samples across 38 different types of cancer.
Weill Cornell Medicine scientists have built the first global database of clinical trials testing a rapidly expanding approach to cancer treatment that involves genetically modifying immune cells to recognize specific targets on a patient’s cancer cells and attack them.
Dr. Simon Scheuring, a professor of physiology and biophysics in anesthesiology at Weill Cornell Medicine has been awarded a prestigious National Institutes of Health Director’s Pioneer Award for a project aimed at solving long-standing mysteries about the structural workings of important proteins.
